Eli Lilly and Company (NYSE:LLY) is acquiring Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on oral therapies for inflammatory diseases. The transaction is valued at approximately $1.2 billion and is expected to close in H1 2026. The agreement has been approved by both companies’ boards, with the purchase price representing a 62% premium to Ventyx’s 30-day average trading price. Eli Lilly develops and sells pharmaceutical products across various therapeutic areas, including oncology and diabetes. The company aims to strengthen its position in the obesity drug market with this acquisition.

Read more at Yahoo Finance: Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences